Resources

This web page provides technical information, resources, and links relevant to microarray patch (also known as MAPs or microneedle patches) development of high priority vaccine and essential medicines. Includes multisectoral information for the community of microarray patch researchers, manufacturers, stakeholders, and technology developers.

A summary of the work led by the Diarrhea Innovations Group, housed at PATH, to submit an application to the World Health Organization's Model List of Essential Medicines for Children for the addition of co-packaged oral rehydration solution (ORS) and zinc as an individual listing. The addition of a co-packaged listing has the potential to reinforce the lifesaving benefits of ORS and zinc in managing childhood diarrhea as a cornerstone for all health care systems involved in diarrhea management.

Environmental enteric dysfunction (EED) is an intestinal disorder common among children living in low-resource settings. EED is associated with increased risk of growth stunting, cognitive deficits, and reduced responsiveness to oral vaccines. This resource provides an overview of PATH's work to develop a prototype assay to quantitate multiple markers of EED, systemic inflammation, growth hormone (GH) resistance, and micronutrients for use in EED clinical research in low-resource settings.

Cryptosporidium is an intestinal protozoan parasite that is a major cause of diarrheal disease among young children in low-resource settings. Beyond diarrheal disease, cryptosporidiosis is associated with other chronic conditions, including growth faltering, environmental enteric dysfunction, and possibly impaired cognitive development. Current therapeutic options are limited, with only one drug, nitazoxanide, approved by the United States Food and Drug Administration. There is only one drug in clinical trials against Cryptosporidium: clofazimine, a repurposed leprosy drug developed more than three decades ago. There are no vaccines for Cryptosporidium approved or in clinical development. This poster summarizes key initiatives to develop new Cryptosporidium drugs, including an overview of PATH's portfolio.